Name: 세계 당뇨병성 신경치료 발궤양 시장 - 2023-2030 - Prime research
SKU: DMPH28
Availability: InStock

보고서 요약(국문)

시장 개요
당뇨병성 신경병증성 족부 궤양 시장 규모는 2023년 XX백만 달러였으며, 2030년까지 XX백만 달러에 이를 것으로 예상되며, 예측 기간(2023-2030년) 동안 연평균 8.4%의 성장률을 보일 것으로 전망됩니다.
하지 절단을 초래하는 가장 흔한 발 질환은 당뇨병성 궤양입니다. 일반의는 당뇨병성 족부 질환의 조기 발견 및 예방에 매우 중요합니다. 당뇨병성 족부 관리는 주요 절단 위험 요인에 대한 심층적인 이해, 정기적인 평가 및 철저한 예방적 관리를 필요로 합니다. 가장 흔한 궤양 발생 위험 요인으로는 말초 동맥 폐쇄성 질환, 구조적 족부 변형 및 당뇨병성 신경병증이 있습니다.

시장 동향
전 세계 당뇨병성 족부 궤양 신경치료 시장 성장을 이끄는 주요 요인은 당뇨병성 족부 궤양 환자 수 증가, 치료 기술 발전, 그리고 특정 유형의 족부 궤양에 적합한 특수 드레싱 제품의 개발입니다.
당뇨병성 족부 궤양 환자 수 증가는 시장 성장을 가속화하는 요인입니다.
당뇨병 환자는 당뇨병성 족부 궤양이 발생하기 쉬우며, 심한 경우 다리 절단이 필요할 수 있습니다. 인슐린을 사용하여 혈당을 조절하는 당뇨병 환자는 족부 궤양 발생 위험이 더 높습니다. 당뇨병 외에도 비만, 신장 질환, 안과 질환, 심장 질환이 있는 사람들도 당뇨병성 족부 궤양이 발생할 수 있습니다. 흡연과 음주 또한 발병 위험을 높입니다.
미국 국립보건원(NIH)에 따르면 전 세계적으로 매년 910만~2,610만 건의 당뇨병성 족부 궤양이 발생합니다. 당뇨병 환자의 15~25%는 평생 동안 당뇨병성 족부 궤양을 경험합니다. 매년 당뇨병 진단을 받는 사람이 늘어남에 따라 당뇨병성 족부 궤양의 유병률은 필연적으로 증가할 것입니다. 당뇨병성 족부 궤양은 어느 연령에서든 발생할 수 있지만, 45세 이상의 당뇨병 환자에게서 가장 흔하게 나타납니다. 미국에서 족부 궤양 환자의 대다수는 라틴계, 아프리카계 미국인, 그리고 아메리카 원주민입니다. 따라서 당뇨병성 족부 궤양 발생률 증가는 시장 성장을 가속화할 것입니다.
고가의 첨단 상처 치료 제품과 당뇨병성 족부 궤양 신경 치료(DME)는 시장 성장을 저해할 것으로 예상됩니다.
당뇨병성 족부 궤양은 당뇨병의 가장 흔한 합병증이자 주요 사망 원인입니다. 세포외 단백질, 치료제 및 기타 치료법의 지속적인 기술 개발로 인해 비용이 증가함에 따라 시장 성장이 둔화될 것으로 예상됩니다.
COVID-19 영향 분석
COVID-19 바이러스는 2019년 12월 발생 이후 75개국 이상으로 확산되었으며, 세계보건기구(WHO)는 이를 공중보건 비상사태로 선포했습니다. 예를 들어, 세계보건기구(WHO)의 연구에 따르면 2021년 7월 현재 전 세계적으로 약 1억 9천만 명이 코로나바이러스(COVID-19)에 감염되었습니다.
COVID-19가 경제에 영향을 미치는 세 가지 주요 방식은 공급과 수요의 직접적인 변화, 유통망의 혼란, 그리고 기업과 금융 시장에 대한 경제적 영향입니다. 중국, 인도, 사우디아라비아, 아랍에미리트, 이집트 등 많은 국가들이 광범위한 봉쇄 조치로 인해 의약품을 한 지역에서 다른 지역으로 운송하는 데 어려움을 겪고 있습니다. 또한, COVID-19 팬데믹은 전 세계 당뇨병성 족부 궤양 치료제 시장의 업계 참여자들에게 여러 측면에서 상당한 장애물을 야기하고 있습니다. 의약품 제형을 만드는 데 필요한 원자재의 공급 부족은 운송 차질로 인한 주요 문제 중 하나입니다. 게다가 COVID-19 환자 및 기타 생명을 위협하는 질병 환자의 증가로 인해 유통업체들은 매장의 제품 수요 변동을 겪고 있습니다.

세그먼트 분석
당뇨병성 족부 궤양 치료용 드레싱 부문은 예측 기간(2022-2029년) 동안 가장 빠른 연평균 성장률(CAGR)을 기록할 것으로 예상됩니다.
고급 상처 드레싱 부문은 전 세계 당뇨병성 족부 궤양 치료 시장을 주도하고 있습니다. 상처 치료용 하이드로겔 드레싱에는 알긴산 드레싱, 하이드로 파이버 드레싱, 수술용 드레싱 등 다양한 종류가 있습니다. 현재 가장 널리 사용되는 상처 치료 유형은 폼 드레싱입니다. 난치성 상처 환자는 고급 상처 드레싱의 도움을 받을 수 있습니다. 이는 천연 생체 고분자로 만들어진 활성 부직포 상처 드레싱입니다. 상처 드레싱의 360도 동적 작용 방식은 효율적인 분비물 조절, 통증 감소, 감염 관리, 적극적인 상처 치유 및 흉터 개선을 가능하게 합니다. 뛰어난 흡수력과 통증 없는 제거는 환자의 편안함을 향상시킵니다. 결과적으로, 상처 드레싱은 다양한 단계의 상처 치료에 널리 사용되고 있으며, 주요 업체들도 신제품을 출시하여 이 카테고리의 성장을 촉진하고 있습니다.

예를 들어, 2022년 10월, 벵갈루루에 본사를 둔 헬시움 메드테크(Healthium Medtech)는 당뇨병으로 인한 다리 및 발 궤양을 포함한 만성 상처 치료를 위한 새로운 상처 드레싱 제품군인 시오럽터 노보(Theruptor Novo)를 출시했습니다. 시오럽터 노보의 출시로 헬시움은 첨단 상처 드레싱 분야에서 이미 시장에 제공하고 있는 자체 솔루션의 범위를 확장했습니다.
또한, 2021년 9월, 미국 기업 휴먼 바이오사이언스(HBS)는 인도 시장에 두 가지 상처 치료 제품을 곧 출시할 것이라고 밝혔습니다. 회사 발표에 따르면 두 제품의 이름은 "메디필(Medifil)"과 "스킨 템프(Skin Temp)"입니다. 이 회사는 곧 인도에서 두 가지 상처 관리 제품인 "메디필"과 "스킨 템프"를 출시할 계획입니다.
지역 분석
북미는 전 세계 당뇨병성 족부 궤양 신경치료 시장에서 가장 큰 시장 점유율을 차지하고 있습니다.
이 연령대에서 가장 흔한 질병은 당뇨병이며, 이는 종종 당뇨병성 족부 궤양을 유발합니다. 사람들의 좌식 생활 방식이 증가함에 따라 당뇨병성 족부 궤양의 유병률이 증가했습니다. 이 지역에서는 두 사람 중 한 명이 당뇨병을 앓고 있어 당뇨병성 족부 궤양 치료에 대한 수요가 증가했습니다. 국제당뇨병연맹(International Diabetes Federation)은 2021년 북미 및 카리브해 지역의 당뇨병 환자 수를 5,100만 명으로 추산했습니다. 2천만 명 이상의 미국인이 말초 신경병증을 겪고 있는 것으로 추정됩니다. 그러나 신경병증 증상을 보이는 모든 사람이 검사를 받는 것은 아니며, 현재 모든 형태의 신경병증을 감지할 수 있는 검사가 개발되지 않았다는 점을 고려하면 실제 수치는 훨씬 더 높을 수 있습니다.
주요 시장 경쟁 심화, 증가하는 의료 GDP 지출, 그리고 당뇨병성 족부궤양 치료에 대한 향상된 보험금 지급이 이 지역 시장 성장에 주로 영향을 미칩니다. 캐나다 당뇨병 협회(2020)에 따르면, 당뇨병은 병원에서 시행되는 하지 절단의 70%를 차지하며, 캐나다 성인의 비외상성 하지 절단의 가장 흔한 원인입니다. 캐나다의 당뇨병 환자는 일반 인구보다 비외상성 하지 절단 위험이 거의 20배 높으며, 이 중 85%는 족부궤양에 선행됩니다.
경쟁 환경
당뇨병성 족부궤양 신경치료 시장은 Medtronic, Organogenesis, Inc, Acelity L.P., Inc, B Braun Melsungen AG, Coloplast Corp, Smith & Nephew Plc, Medline Industries, Inc, 3M Healthcare, Molnlycke Health Care AB, Hyper oil 등 국내외 기업들이 경쟁하는 비교적 경쟁적인 시장입니다. 주요 기업들은 신제품 출시, 인수합병 등 다양한 성장 전략을 채택하고 있습니다. 파트너십과 협력은 시장 성장에 기여하고 있습니다. 예를 들어, 2022년 6월 Smith+Nephew는 1억 달러 이상을 투자하여 최고 수준의 연구 개발, 제조 및 다목적 사무실 건물을 건설할 예정입니다. 영국 정부의 자금 지원도 개발 자금 마련에 도움이 될 것입니다. 이 새로운 공장은 향후 10년간 100억 달러 이상의 매출을 지원할 것으로 예상됩니다.
하이퍼 오일(Hyper Oil).
개요: 이 제품의 특허권은 2005년 RI.MOS에서 획득했으며, 2006년부터 인체 대상 궤양 및 욕창 치료 임상 시험이 시작되었습니다. 이탈리아 토스카나 주 루카에 위치한 바르반티니 병원(Clinica Barbantini)의 궤양학과에서 실시한 초기 결과는 가장 낙관적인 예측을 뛰어넘었습니다. 이탈리아 시장용 브랜드인 Holoil과 국제 시장용 브랜드인 Hyperoil은 2008년 CE Class IIb 의료기기 승인을 받았습니다. 2009년에는, RI.MOS는 이탈리아 시장에서 제품 홍보를 위해 수의용 Hypermix와 인체용 Holoil 브랜드를 출시했습니다(2011년).
제품 포트폴리오:
빠른 치유 고급 상처 드레싱: Hyperoil은 감염 예방, 상피 재생 지원, 섬유소 용해 작용 및 기타 이점을 제공합니다. 조직 복구의 모든 단계에서 필요에 따라 보호 및/또는 흡수를 위한 보조 드레싱만 있으면 되며, 그 외 모든 필수 기능은 자체적으로 수행합니다.
글로벌 당뇨병성 신경 치료 족부 궤양 시장 보고서는 약 45개 이상의 시장 데이터 표, 40개 이상의 그림 및 약 200페이지 분량의 자료를 제공합니다.

보고서 요약(영어 원문)

Market Overview
Diabetic Neuropathic Foot Ulcers Market size was valued at US$ XX million in 2023 and is estimated to reach US$ XX million by 2030, growing at a CAGR of 8.4% during the forecast period (2023-2030).
The most frequent foot wounds resulting in lower extremity amputation are diabetic ulcers. General practitioners are crucial in the early detection or prevention of diabetic foot problems. The management of the diabetic foot necessitates in-depth familiarity with the primary amputation risk factors, routine evaluation, and meticulous preventive maintenance. The most frequent ulcer-forming risk factors include peripheral artery occlusive disease, structural foot deformity, and diabetic neuropathy.
Market Dynamics
The major factors driving the global diabetic neurotherapy foot ulcers market are the expansion is accelerated by the increasing number of diabetic foot ulcers, the market will be driven by treatment technology advancement and there are specific dressings available for a particular type of foot ulcer.
The expansion is accelerated by the increasing number of diabetic foot ulcers.
Patients with diabetes are prone to developing diabetic foot ulcers, which can necessitate the amputation of the leg. Patients with diabetes who use insulin to control their condition are more likely to develop a foot ulcer. In addition to diabetes, individuals with obesity, kidney, eye, and heart issues may also develop diabetic foot ulcers. Use of tobacco and alcohol both raises the risk of the illness.
According to the National Institutes of Health (U.S.A.), between 9.1 and 26.1 million diabetic foot ulcers occur annually over the world. In their lifetime, 15 to 25% of people with diabetes mellitus will get a diabetic foot ulcer. The prevalence of diabetic foot ulcers will inevitably rise as more people are diagnosed with diabetes each year. Although diabetic foot ulcers can develop at any age, they are most common in those with diabetes mellitus who are over 45. The majority of Americans with foot ulcers are Latinos, African Americans, and Native Americans. Thus, the growth is sped up by an increase in the incidence of diabetic foot ulcers.
Costly advanced wound care products and therapies of diabetic neurotherapy foot ulcers (DME) is expected to hamper the market’s growth.
A diabetic foot ulcer is the most prevalent consequence of diabetes and a substantial cause of death. It is anticipated that ongoing technical developments in therapeutic alternatives will slow the market's growth because extracellular proteins, therapeutic agents, and other options have become too expensive.
COVID-19 Impact Analysis
The virus has spread to over 75 countries since the COVID-19 viral outbreak in December 2019, and the World Health Organization declared it a public health emergency. For instance, as of July 2021, about 190 million people worldwide were infected due to the coronavirus (COVID-19) manifestation, according to a study from the World Health Organization.
Three main ways that COVID-19 can affect the economy are directly altering supply and demand, disrupting distribution networks, and having an economic impact on businesses and financial markets. Many nations, including China, India, Saudi Arabia, the United Arab Emirates, Egypt, and others, have difficulty moving pharmaceuticals from one location to another due to widespread lockdowns. Furthermore, the COVID-19 pandemic poses significant obstacles for industry participants in the worldwide diabetic foot ulcer therapy market on numerous fronts. The availability of raw materials required to make pharmaceutical formulations is one of the major problems caused by transportation irregularities. Additionally, because of a rise in patients with COVID-19 and other life-threatening illnesses, distributors see irregular demand for their products from stores.
Segment Analysis
The wound care dressing diabetic Neurotherapy foot ulcers-type segment is expected to grow at the fastest CAGR during the forecast period (2022-2029)
The advanced wound dressings segment dominated the market for treating diabetic foot ulcers worldwide. There are many kinds of hydrogel dressings for wound treatment, including alginate dressings, hydro fiber dressings, surgical dressings, and others. Foam dressings are the most popular type of wound care treatment nowadays. Patients who have non-healing wounds can benefit from advanced wound care dressings. It is an active non-woven wound dressing made entirely of natural biopolymer. The 360-degree, dynamic mode of action of wound care dressings allows for efficient discharge control, pain reduction, infection control, active wound healing, and scar improvement. The excellent absorption capacity and painless removal of wound care dressings enhance patient comfort. As a result, they are widely employed for the care of wounds in various phases, and key players are also releasing new products, which boosts the market for this category.
For instance, in October 2022, A new line of wound dressings named Theruptor Novo was introduced by Bengaluru-based Healthium Medtech for treating chronic wounds, including leg and foot ulcers caused by diabetes. With the introduction of Theruptor Novo, Healthium expands the range of proprietary solutions it already offers in the market for advanced wound dressings.
For instance, in September 2021, The American Company Human Biosciences (HBS) hinted that it would soon launch two wound care products in the Indian market. The two items have the names "Medifil" and "Skin Temp, according to an announcement from the company. The company plans to offer two of its wound care management products, "Medifil" and "Skin Temp" in India soon.
Geographical Analysis
North America holds the largest market share in the global diabetic neurotherapy foot ulcers market.
The most prevalent illness in this age range is diabetes, which frequently results in diabetic foot ulcers. The prevalence of diabetic foot ulcers has increased due to people living more sedentary lifestyles. In this region, diabetes affects one in two people, which has helped to increase the demand for diabetic foot ulcer treatments. The International Diabetes Federation 2021 estimates that 51 million people in North America and the Caribbean now have diabetes. More than 20 million Americans are thought to experience peripheral neuropathy. However, given that not everyone who displays neuropathy symptoms is tested for the condition and that tests are currently not developed to detect all forms of neuropathy, this number may be much higher.
Major market competitors, rising healthcare GDP spending, and enhanced reimbursement for DFU therapy primarily influence the region's market growth. According to the Canadian Diabetes Association 2020, diabetes accounts for 70% of lower limb amputations carried out in hospitals and are the most common reason for non-traumatic lower limb amputation in Canadian adults. Canadian individuals with diabetes are nearly 20 times more likely than the general population to have non-traumatic lower limb amputations, 85% of which are preceded by a foot ulcer.
Competitive Landscape
The diabetic neurotherapy foot ulcers market is moderately competitive with local and global companies’ presence Medtronic, Organogenesis, Inc, Acelity L.P., Inc, B Braun Melsungen AG, Coloplast Corp, Smith & Nephew Plc, Medline Industries, Inc, 3M Healthcare, Molnlycke Health Care AB, Hyper oil and more. The key players are adopting various growth strategies such as product launches, mergers & acquisitions, partnerships, and collaborations, contributing to the market’s growth. For instance, in June 2022, Smith+Nephew will spend over $100 million to build a top-notch research and development, manufacturing, and flexible office building. A funding from the UK government will also help to fund the development. In its first ten years of operation, the new factory is anticipated to support sales of more than $10 billion.
Hyper Oil.
Overview: The product's patent license was obtained by RI.MOS in 2005, and clinical trials for the treatment of ulcers and bedsores in humans commenced in 2006. Even the most hopeful predictions were surpassed by the initial results of the Clinica Barbantini of Lucca, Tuscany, one of the most significant National reference centers, conducted by the Department of Vulnology. Holoil (a brand for the Italian market) and Hyperoil (a brand for international markets) received CE approval as Class IIb Medical Devices in 2008. In 2009, RI.MOS launched the Hypermix for Veterinary Use and Holoil for Human Use brands to promote the product in the Italian market (in 2011).
Product Portfolio:
Fast Healing Advanced Wound Dressing: Infection prevention, re-epithelialization support, fibrinolytic action, and other benefits are provided by hyperoil. At all stages of tissue repair, it only needs the assistance of secondary dressings to protect and/or absorb, as necessary, while carrying out all other essential tasks on its own.
The global diabetic neurotherapy foot ulcers market report would provide access to approx.: 45+market data table, 40+figures and 200 (approximate) pages.

상세 목차

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Market Definition and Overview
3. Executive Summary
4. Market Dynamics
4.1. Market Impacting Factors
4.1.1. Drivers
4.1.1.1. The expansion is accelerated by the increasing number of diabetic foot ulcers
4.1.1.2. The market will be driven by treatment technology advancement
4.1.2. Restraints:
4.1.2.1. Costly advanced wound care products and therapies restrain market expansion
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1 Porter's Five Forces Analysis
5.2 Supply Chain Analysis
5.3 Pricing Analysis
5.4 Regulatory Analysis
6. COVID-19 Analysis
6.1. Analysis of Covid-19 on the Market
6.1.1. Before COVID-19 Market Scenario
6.1.2. Present COVID-19 Market Scenario
6.1.3. After COVID-19 or Future Scenario
6.2. Pricing Dynamics Amid Covid-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During the Pandemic
6.5. Manufacturer’s Strategic Initiatives
6.6. Conclusion
7. By Ulcer Type
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Ulcer Type
7.1.2. Market Attractiveness Index, By Ulcer Type
7.2. Neuropathic Ulcers
7.2.1. Introduction
7.2.2. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
7.3. Ischemic Ulcers
7.4. Neuro-Ischemic Ulcers
8. By Treatment Type
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
8.1.2. Market Attractiveness Index, By Treatment Type
8.2. Wound Care Dressings
8.2.1. Introduction
8.2.2. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
8.3. Biologics
8.4. Others
9. By End user
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End user
9.1.2. Market Attractiveness Index, By End user
9.2. Hospitals
9.2.1. Introduction
9.2.2. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
9.3. Specialty Clinics
9.4. Long term Care Centres
9.5. Ambulatory Surgical Centres
9.6. Home Care setting
10. By Region
10.1. Introduction
10.1.1. Market Size AnalysisUS$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
10.1.2. Market Attractiveness Index, By Region
10.2. North America
10.2.1. Introduction
10.2.2. Key Region-Specific Dynamics
10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Ulcer Type
10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End user
10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.2.6.1. U.S.
10.2.6.2. Canada
10.2.6.3. Mexico
10.3. Europe
10.3.1. Introduction
10.3.2. Key Region-Specific Dynamics
10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Ulcer Type
10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End user
10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.3.6.1. Germany
10.3.6.2. U.K.
10.3.6.3. France
10.3.6.4. Italy
10.3.6.5. Spain
10.3.6.6. Rest of Europe
10.4. South America
10.4.1. Introduction
10.4.2. Key Region-Specific Dynamics
10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Ulcer Type
10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End user
10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.4.6.1. Brazil
10.4.6.2. Argentina
10.4.6.3. Rest of South America
10.5. Asia Pacific
10.5.1. Introduction
10.5.2. Key Region-Specific Dynamics
10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Ulcer Type
10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End user
10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.5.6.1. China
10.5.6.2. India
10.5.6.3. Japan
10.5.6.4. Australia
10.5.6.5. Rest of Asia Pacific
10.6. Middle East and Africa
10.6.1. Introduction
10.6.2. Key Region-Specific Dynamics
10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Ulcer Type
10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End user
11. Competitive Landscape
11.1. Key Developments and Strategies
11.2. Company Share Analysis
11.3. Products Benchmarking
11.4. List of Key Companies to Watch
12. Company Profiles
12.1. Medtronic
12.1.1. Company Overview
12.1.2. Product Portfolio and Description
12.1.3. Key Highlights
12.1.4. Financial Overview
12.2. Organogenesis, Inc
12.3. Acelity L.P., Inc
12.4. B Braun Melsungen AG
12.5. Coloplast Corp
12.6. Medline Industries, Inc
12.7. 3M Healthcare
12.8. Molnlycke Health Care AB
12.9. Hyper oil
12.10. Smith & Nephew Plc.
LIST NOT EXHAUSTIVE
13. Global Diabetic Neurotherapy Foot Ulcers Market – DataM
13.1. Appendix
13.2. About Us and Application
13.3. Contact Us

언급된 주요 기업들

Medtronic, Organogenesis, Inc, Acelity L.P., Inc, B Braun Melsungen AG, Coloplast Corp, Medline Industries, Inc, 3M Healthcare, Molnlycke Health Care AB, Hyper oil, Smith & Nephew Plc.

표 목록 (Tables)

List of Tables Table 1 Global Diabetic Neurotherapy Foot Ulcers Market Value, By Ulcer Type, 2022, 2027 & 2031 ($ Million)

Table 2 Global Diabetic Neurotherapy Foot Ulcers Market Value, By Treatment Type, 2022, 2027 & 2031 ($ Million)

Table 3 Global Diabetic Neurotherapy Foot Ulcers Market Value, By End-User, 2022, 2027 & 2031 ($ Million)

Table 4 Global Diabetic Neurotherapy Foot Ulcers Market Value, By Region, 2022, 2027 & 2031 ($ Million)

Table 5 Global Diabetic Neurotherapy Foot Ulcers Market Value, By Ulcer Type, 2022, 2027 & 2031 ($ Million)

Table 6 Global Diabetic Neurotherapy Foot Ulcers Market Value, By Ulcer Type, 2022-2031 ($ Million)

Table 7 Global Diabetic Neurotherapy Foot Ulcers Market Value, By Treatment Type, 2022, 2027 & 2031 ($ Million)

Table 8 Global Diabetic Neurotherapy Foot Ulcers Market Value, By Treatment Type, 2022-2031 ($ Million)

Table 9 Global Diabetic Neurotherapy Foot Ulcers Market Value, By End-User, 2022, 2027 & 2031 ($ Million)

Table 10 Global Diabetic Neurotherapy Foot Ulcers Market Value, By End-User, 2022-2031 ($ Million)

Table 11 Global Diabetic Neurotherapy Foot Ulcers Market Value, By Region, 2022, 2027 & 2031 ($ Million)

Table 12 Global Diabetic Neurotherapy Foot Ulcers Market Value, By Region, 2022-2031 ($ Million)

Table 13 North America Diabetic Neurotherapy Foot Ulcers Market Value, By Ulcer Type, 2022-2031 ($ Million)

Table 14 North America Diabetic Neurotherapy Foot Ulcers Market Value, By Treatment Type, 2022-2031 ($ Million)

Table 15 North America Diabetic Neurotherapy Foot Ulcers Market Value, By End-User, 2022-2031 ($ Million)

Table 16 North America Diabetic Neurotherapy Foot Ulcers Market Value, By Country, 2022-2031 ($ Million)

Table 17 South America Diabetic Neurotherapy Foot Ulcers Market Value, By Ulcer Type, 2022-2031 ($ Million)

Table 18 South America Diabetic Neurotherapy Foot Ulcers Market Value, By Treatment Type, 2022-2031 ($ Million)

Table 19 South America Diabetic Neurotherapy Foot Ulcers Market Value, By End-User, 2022-2031 ($ Million)

Table 20 South America Diabetic Neurotherapy Foot Ulcers Market Value, By Country, 2022-2031 ($ Million)

Table 21 Europe Diabetic Neurotherapy Foot Ulcers Market Value, By Ulcer Type, 2022-2031 ($ Million)

Table 22 Europe Diabetic Neurotherapy Foot Ulcers Market Value, By Treatment Type, 2022-2031 ($ Million)

Table 23 Europe Diabetic Neurotherapy Foot Ulcers Market Value, By End-User, 2022-2031 ($ Million)

Table 24 Europe Diabetic Neurotherapy Foot Ulcers Market Value, By Country, 2022-2031 ($ Million)

Table 25 Asia-Pacific Diabetic Neurotherapy Foot Ulcers Market Value, By Ulcer Type, 2022-2031 ($ Million)

Table 26 Asia-Pacific Diabetic Neurotherapy Foot Ulcers Market Value, By Treatment Type, 2022-2031 ($ Million)

Table 27 Asia-Pacific Diabetic Neurotherapy Foot Ulcers Market Value, By End-User, 2022-2031 ($ Million)

Table 28 Asia-Pacific Diabetic Neurotherapy Foot Ulcers Market Value, By Country, 2022-2031 ($ Million)

Table 29 Middle East & Africa Diabetic Neurotherapy Foot Ulcers Market Value, By Ulcer Type, 2022-2031 ($ Million)

Table 30 Middle East & Africa Diabetic Neurotherapy Foot Ulcers Market Value, By Treatment Type, 2022-2031 ($ Million)

Table 31 Middle East & Africa Diabetic Neurotherapy Foot Ulcers Market Value, By End-User, 2022-2031 ($ Million)

Table 32 Medtronic: Overview

Table 33 Medtronic: Product Portfolio

Table 34 Medtronic: Key Developments

Table 35 Organogenesis, Inc: Overview

Table 36 Organogenesis, Inc: Product Portfolio

Table 37 Organogenesis, Inc: Key Developments

Table 38 Acelity L.P., Inc: Overview

Table 39 Acelity L.P., Inc: Product Portfolio

Table 40 Acelity L.P., Inc: Key Developments

Table 41 B Braun Melsungen AG: Overview

Table 42 B Braun Melsungen AG: Product Portfolio

Table 43 B Braun Melsungen AG: Key Developments

Table 44 Coloplast Corp: Overview

Table 45 Coloplast Corp: Product Portfolio

Table 46 Coloplast Corp: Key Developments

Table 47 Medline Industries, Inc: Overview

Table 48 Medline Industries, Inc: Product Portfolio

Table 49 Medline Industries, Inc: Key Developments

Table 50 3M Healthcare: Overview

Table 51 3M Healthcare: Product Portfolio

Table 52 3M Healthcare: Key Developments

Table 53 Molnlycke Health Care AB: Overview

Table 54 Molnlycke Health Care AB: Product Portfolio

Table 55 Molnlycke Health Care AB: Key Developments

Table 56 Hyper oil : Overview

Table 57 Hyper oil : Product Portfolio

Table 58 Hyper oil : Key Developments

Table 59 Smith & Nephew Plc: Overview

Table 60 Smith & Nephew Plc: Product Portfolio

Table 61 Smith & Nephew Plc: Key Developments

그림 목록 (Figures)

List of Figures Figure 1 Global Diabetic Neurotherapy Foot Ulcers Market Share, By Ulcer Type, 2022 & 2031 (%)

Figure 2 Global Diabetic Neurotherapy Foot Ulcers Market Share, By Treatment Type, 2022 & 2031 (%)

Figure 3 Global Diabetic Neurotherapy Foot Ulcers Market Share, By End-User, 2022 & 2031 (%)

Figure 4 Global Diabetic Neurotherapy Foot Ulcers Market Share, By Region, 2022 & 2031 (%)

Figure 5 Global Diabetic Neurotherapy Foot Ulcers Market Value, 2022-2031 ($ Million)

Figure 6 Global Diabetic Neurotherapy Foot Ulcers Market Y-o-Y Growth, By Ulcer Type, 2021-2029 (%)

Figure 7 Neuropathic Ulcers: Global Diabetic Neurotherapy Foot Ulcers Market Value, 2022-2031 ($ Million)

Figure 8 "Ischemic Ulcers: Global Diabetic Neurotherapy Foot Ulcers Market Value, 2022-2031 ($ Million)"

Figure 9 "Neuro-Ischemic Ulcers: Global Diabetic Neurotherapy Foot Ulcers Market Value, 2022-2031 ($ Million)"

Figure 10 Global Diabetic Neurotherapy Foot Ulcers Market Y-o-Y Growth, By Treatment Type, 2021-2029 (%)

Figure 11 Wound Care Dressings: Global Diabetic Neurotherapy Foot Ulcers Market Value, 2022-2031 ($ Million)

Figure 12 "Biologics: Global Diabetic Neurotherapy Foot Ulcers Market Value, 2022-2031 ($ Million)"

Figure 13 "Others: Global Diabetic Neurotherapy Foot Ulcers Market Value, 2022-2031 ($ Million)"

Figure 14 Global Diabetic Neurotherapy Foot Ulcers Market Y-o-Y Growth, By End-User, 2021-2029 (%)

Figure 15 Hospitals: Global Diabetic Neurotherapy Foot Ulcers Market Value, 2022-2031 ($ Million)

Figure 16 Specialty Clinics: Global Diabetic Neurotherapy Foot Ulcers Market Value, 2022-2031 ($ Million)

Figure 17 Long term Care Centres: Global Diabetic Neurotherapy Foot Ulcers Market Value, 2022-2031 ($ Million)

Figure 18 Ambulatory Surgical Centres: Global Diabetic Neurotherapy Foot Ulcers Market Value, 2022-2031 ($ Million)

Figure 19 Home Care setting: Global Diabetic Neurotherapy Foot Ulcers Market Value, 2022-2031 ($ Million)

Figure 20 Global Diabetic Neurotherapy Foot Ulcers Market Y-o-Y Growth, By Region, 2021-2029 (%)

Figure 21 North America Diabetic Neurotherapy Foot Ulcers Market Value, 2022-2031 ($ Million)

Figure 22 North America Diabetic Neurotherapy Foot Ulcers Market Share, By Ulcer Type, 2022 & 2031 (%)

Figure 23 North America Diabetic Neurotherapy Foot Ulcers Market Share, By Treatment Type, 2022 & 2031 (%)

Figure 24 North America Diabetic Neurotherapy Foot Ulcers Market Share, By End-User, 2022 & 2031 (%)

Figure 25 North America Diabetic Neurotherapy Foot Ulcers Market Share, By Country, 2022 & 2031 (%)

Figure 26 South America Diabetic Neurotherapy Foot Ulcers Market Value, 2022-2031 ($ Million)

Figure 27 South America Diabetic Neurotherapy Foot Ulcers Market Share, By Ulcer Type, 2022 & 2031 (%)

Figure 28 South America Diabetic Neurotherapy Foot Ulcers Market Share, By Treatment Type, 2022 & 2031 (%)

Figure 29 South America Diabetic Neurotherapy Foot Ulcers Market Share, By End-User, 2022 & 2031 (%)

Figure 30 South America Diabetic Neurotherapy Foot Ulcers Market Share, By Country, 2022 & 2031 (%)

Figure 31 Europe Diabetic Neurotherapy Foot Ulcers Market Value, 2022-2031 ($ Million)

Figure 32 Europe Diabetic Neurotherapy Foot Ulcers Market Share, By Ulcer Type, 2022 & 2031 (%)

Figure 33 Europe Diabetic Neurotherapy Foot Ulcers Market Share, By Treatment Type, 2022 & 2031 (%)

Figure 34 Europe Diabetic Neurotherapy Foot Ulcers Market Share, By End-User, 2022 & 2031 (%)

Figure 35 Europe Diabetic Neurotherapy Foot Ulcers Market Share, By Country, 2022 & 2031 (%)

Figure 36 Asia-Pacific Diabetic Neurotherapy Foot Ulcers Market Value, 2022-2031 ($ Million)

Figure 37 Asia-Pacific Diabetic Neurotherapy Foot Ulcers Market Share, By Ulcer Type, 2022 & 2031 (%)

Figure 38 Asia-Pacific Diabetic Neurotherapy Foot Ulcers Market Share, By Treatment Type, 2022 & 2031 (%)

Figure 39 Asia-Pacific Diabetic Neurotherapy Foot Ulcers Market Share, By End-User, 2022 & 2031 (%)

Figure 40 Asia-Pacific Diabetic Neurotherapy Foot Ulcers Market Share, By Country, 2022 & 2031 (%)

Figure 41 Middle East & Africa Diabetic Neurotherapy Foot Ulcers Market Value, 2022-2031 ($ Million)

Figure 42 Middle East & Africa Diabetic Neurotherapy Foot Ulcers Market Share, By Ulcer Type, 2022 & 2031 (%)

Figure 43 Middle East & Africa Diabetic Neurotherapy Foot Ulcers Market Share, By Treatment Type, 2022 & 2031 (%)

Figure 44 Middle East & Africa Diabetic Neurotherapy Foot Ulcers Market Share, By End-User, 2022 & 2031 (%)

Figure 45 Medtronic: Financials

Figure 46 Organogenesis, Inc: Financials

Figure 47 Acelity L.P., Inc: Financials

Figure 48 B Braun Melsungen AG: Financials

Figure 49 Coloplast Corp: Financials

Figure 50 Medline Industries, Inc: Financials

Figure 51 3M Healthcare: Financials

Figure 52 Molnlycke Health Care AB: Financials

Figure 53 Hyper oil : Financials

Figure 54 Smith & Nephew Plc: Financials

세계 당뇨병성 신경치료 발궤양 시장 – 2023-2030

Global Diabetic Neurotherapy Foot Ulcers Market - 2023-2030